艾拉莫德与环磷酰胺序贯硫唑嘌呤治疗活动性狼疮肾炎比较:iGeLU研究方案
本研究为多中心、随机、52周阳性药对照试验,计划纳入120例经活检证实的活动性狼疮肾炎患者,头对头比较艾拉莫德与环磷酰胺诱导后硫唑嘌呤维持的疗效。主要终点为第52周肾脏缓解率(完全+部分缓解),采用非劣效性检验。
要点
- 艾拉莫德在难治性狼疮肾炎观察性研究中显示潜力,但需随机对照验证。
- 试验分两阶段:前24周诱导期对比环磷酰胺,后24周维持期对比硫唑嘌呤。
- 主要终点为52周肾脏缓解率,采用非劣效性假设检验。
核心结论
- 本试验旨在验证艾拉莫德能否作为活动性狼疮肾炎的替代诱导或维持治疗。
研究设计与样本
- 多中心、随机、52周平行阳性药对照研究,计划纳入120例(每组60例)经活检证实的活动性狼疮肾炎患者。
- 患者来自中国6个研究中心,随机分配至试验组和对照组。
- 前24周艾拉莫德与环磷酰胺对比作为诱导治疗,后24周艾拉莫德与硫唑嘌呤对比作为维持治疗。
关键数值与推荐
- 主要结局为第52周肾脏缓解率(包括完全缓解和部分缓解),采用非劣效性假设检验分析。
- 至少20-35%的狼疮肾炎患者会出现复发或治疗无效,药物不耐受也较常见。
临床怎么用
- 若达到非劣效性,艾拉莫德可能成为活动性狼疮肾炎的替代诱导或维持治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease that can involve multiple organs or systems. Lupus nephritis (LN) is associated with high mortality and morbidity. However, plenty of patients do not respond to present treatment or relapse. Iguratimod (IGU) is a new small molecular, anti-rheumatic drug and has shown the potential for drug repurposing from rheumatoid arthritis (RA) to LN treatment. It has been approved for treating RA in northeast Asia. Beyond expectation in a recent observational study, over 90% of thirteen refractory LN patients responded to iguratimod monotherapy in 24 weeks, with no steroids dose increasing or any other medication add-on during the entire follow-up. METHODS/DESIGN: This study is a multi-center, randomized, 52-week parallel positive drug-controlled study. The study was designed as a head-to-head comparison between the iguratimod and present first-line therapy on LN patients. A total of 120 patients (60 patients each group) is in the enrolling plan. All enrolled patients are assigned randomly into trial and control groups. The patients will be selected from six study sites in China and will all have biopsy-proven active lupus nephritis. In the first 24 weeks of the trial, IGU is compared with cyclophosphamide as an induction therapy, and in the second 24 weeks, IGU is compared with azathioprine as a maintenance therapy. The primary outcome is renal remission rate including both complete remission and partial remission at week 52, which will be analyzed using a non-inferiority hypothesis test. DISCUSSION: Most patients diagnosed with SLE will develop LN within 5 years and LN remains a major cause of morbidity and death for SLE patients. Although some medications are proven effective for the treatment of this condition, at least 20-35% LN patients have to suffer from relapse or ineffective treatment and medication intolerance is also frequent. This trial is designed to demonstrate whether iguratimod can be used as an alternative induction or maintenance therapy in subjects who have lupus nephritis. Data from this study will provide an evidence on whether or not iguratimod should be recommended to active LN patients. TRIAL REGISTRATION: ClinicalTrials.gov NCT02936375 . Registered on October 18, 2016.
引用
- Yan Q, Du F, Kang Y, et al. Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study). Trials. 2021. PMID: 34380536. doi:10.1186/s13063-021-05475-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。